A research team have discovered a new mechanism by which elovanoids may protect retinal and brain cells against neurodegenerative diseases such as Alzheimer’s and age-related macular degeneration.
A study of the differences between healthy brains and those with Alzheimer’s disease has produced the largest dataset of its type ever.
Researchers have determined that the blood–brain barrier could be used as a possible biomarker for Alzheimer’s disease; this could potentially result in earlier diagnosis of the disease.
